ライフサイエンスコーパス: PAK

1 PAK activation increased MLC and MYPT1 phosphorylation i

2 PAK inactivation led to obliteration of social recogniti

3 PAK inhibition had the opposite results.

4 PAK inhibitors did not interfere with G protein-coupled

5 PAK mediates both flow-induced permeability and matrix-s

6 PAK protein inhibition, in particular, markedly inactiva

7 PAK regulated MLC phosphorylation in an activity-depende

8 PAK translocated the epithelia as early as 1 hour after

9 PAK transplant recipients who receive both organs have a

10 PAK-mediated phosphorylation of PREX2 reduced GEF activi

11 PAKs are evolutionally conserved and widely expressed in

12 PAKs are subdivided into two groups: type I PAKs (PAK1,

13 PAKs contain extensive similarities in sequence and doma

14 TA vs. SPK, hazard ratio [HR]=2.29, P=0.020; PAK vs. SPK, HR=2.73, P=0.003) and acute pancreas reject

15 ultiinstitutional retrospective study of 126 PAK transplantation recipients who had a functioning pan

16 Pancreas graft failure occurred in 14 PAK and two PRT patients with a mean follow-up of 61.6 +

17 phosphorylation by p(21)-activated kinase 3 (PAK) and calmodulin on the 22 kDa C-terminal fragment of

18 er Shank3 knockdown, which was occluded by a PAK inhibitor.

19 defects and conversely, overexpression of a PAK kinase was able to rescue the loss of RhoU cardiac d

20 Molecular Cell, Long et al. now show that a PAK-phosphorylated alternate-spliced isoform of the ster

21 ound that PREX2 was phosphorylated through a PAK-dependent mechanism.

22 ng dendritic spine morphology, in part via a PAK/ERK1/2-dependent pathway, and provide mechanistic in

23 the upstream pathway by which flow activates PAK (integrin activation, Rac).

24 lopment and reveal that RAC1(P29S) activates PAK, AKT, and a gene expression program initiated by the

25 Whereas shear stress activates PAK in endothelial cells on a fibronectin matrix, baseme

26 by its membrane-localized upstream activator PAK.

27 ent for either other integrins or additional PAK family members.

28 expression of the dgcP gene in P. aeruginosa PAK led to increased exopolysaccharide production and up

29 pv. savastanoi NCPPB 3335 and P. aeruginosa PAK reduced their virulence in olive plants and in a mou

30 to the pyocin sensitive strain P. aeruginosa PAK.

31 llowing LPA stimulation, but does not affect PAK-meditated lamellipodia and filopodia formation follo

32 associated with kidney allograft loss after PAK include impaired renal function in the 3 months befo

33 ney and pancreas) and patient survival after PAK.

34 All PAK recipients are alive with functioning kidney grafts,

35 We propose that all PAKs contain cell-cell boundary-targeting motifs but tha

36 thymocytes with a knockout mutation in alpha-PAK (p21-activated kinase)-interacting exchange factor (

37 between CTLA-4-PKC-eta and the GIT2-alphaPIX-PAK complex, an IS-localized focal adhesion complex.

38 vation of its downstream effectors Rac-1 and PAK were increased in the NAc of cocaine-sensitized rats

39 included 252 recipients (SPK 60, PTA 71, and PAK 121), 53% men, age 43.9+/-9 years, followed for 6.3

40 kidney, pancreas transplantation alone, and PAK transplant recipients, 54.7%, 37.3%, and 58.8% were

41 cal synapse development through the EphB and PAK signaling pathways.

42 xes: (1) a complex of SCRIB, ARHGEF, GIT and PAK (p21-activated kinase), and (2) a complex of SCRIB,

43 Furthermore, survival of PAO1 and PAK strains in the cornea and development of corneal dis

44 PAO1- and PAK-infected corneas developed severe disease with prono

45 h uremic diabetic waitlist patients, SPK and PAK recipients showed similar overall patient survival.

46 Pancreas-graft outcomes in SPK and PAK were equivalent in our study, but our specific popul

47 Unexpectedly, ARF and PAKs are organized on adjacent surfaces of EspG, indicat

48 EphB2, Cdc42, and PAKs are broadly capable of controlling dendritic spine

49 Both SAP102 and PAKs are associated with X-linked mental retardation in

50 insulin, neuregulin, and IGF1 treatment are PAK-dependent and lead to a reduction in PREX1 binding t

51 and some of their effector proteins such as PAK and ROCK, are likely anti-cancer targets for treatin

52 paired renal function in the 3 months before PAK, proteinuria, the occurrence of a post-PAK kidney re

53 hogenesis, a complex comprising the betaPIX (PAK-interacting exchange factor beta) and class I PAKs (

54 Although a role for the Scrib-betaPIX-PAK signaling complex in promoting membrane protrusion a

55 o received a living donor kidney followed by PAK.

56 e mechanisms of PREX1 negative regulation by PAKs within receptor tyrosine kinase and GPCR-stimulated

57 and comparison subjects, and levels of CDC42-PAK-LIMK pathway messenger RNAs were measured by quantit

58 yperpermeability by activating the Rac/Cdc42/PAK pathway, with concomitant inhibition of the Rho path

59 In BRAFi-resistant cells, PAKs phosphorylate CRAF and MEK to reactivate ERK.

60 their large and flexible ATP binding cleft, PAKs, particularly group I PAKs (PAK1, -2, and -3), are

61 The analysis compared PAK and SPK candidates and recipients.

62 g is required, but not sufficient, to direct PAKs to cell-cell contacts and that an N-terminal polyba

63 the assembly of clathrin-coated pits, and DN PAK-1, an obligate mediator of macropinocytosis, had no

64 lopment by mediating EphB and its downstream PAK signaling pathway.

65 ntinued to recruit and activate its effector PAK, even upon serum stimulation.

66 nstream activation of the signaling effector PAK but not ERK, thereby affecting front-rear polarity a

67 cells on fibronectin, resulting in enhanced PAK activation, NF-kappaB phosphorylation, ICAM-1 expres

68 KA by PKA inhibitor (PKI) injection enhanced PAK activation and inflammatory gene expression.

69 , and -3), are difficult to drug; hence, few PAK inhibitors with satisfactory kinase selectivity and

70 Diabetic candidates for PAK with any of these conditions should be counseled reg

71 The most notable decrease occurred for PAK transplants, possibly due in part to decreases in nu

72 , and lack of data between kidney and PT for PAK.

73 rict IF transport and reveals a new role for PAK and ROCK in the regulation of IF precursor transport

74 e Akt, our observations support the role for PAK-1 as a potential target for therapeutic intervention

75 Pancreas graft survival was similar for PAK and PRT at 1 year (88.2% vs. 100%) and 3 years (85.1

76 outside institutions and referred to us for PAK.

77 ain PAO1, and we found that a mexS gene from PAK confers high T3SS expression in the PAO1 background.

78 in subunits Gbeta1, Ggamma2, and/or Ggamma5, PAK-associated guanine nucleotide exchange factor (betaP

79 We propose that a Rac>PAK signaling pathway needed for rapid stabilization of

80 ing with the p21-activating kinase homologue PAK-1 and acting in this pathway, thereby identifying th

81 r(203) is mediated by kinases of the class I PAK subfamily, specifically 1) exposing cells to four st

82 of orally available ATP-competitive Group I PAK inhibitors with significant potential for the treatm

83 ies based on a benzimidazole core, a group I PAK selective series based on a pyrido[2,3-d]pyrimidine-

84 but that the variable region prevents type I PAK accumulation at junctions.

85 In contrast, the type I PAK, PAK1, does not localize to cell-cell contacts.

86 nteracting exchange factor beta) and class I PAKs (p21-activated kinases) is recruited to adherens ju

87 TP binding cleft, PAKs, particularly group I PAKs (PAK1, -2, and -3), are difficult to drug; hence, f

88 We propose a model whereby group I PAKs act downstream of Rac to organize the actin filamen

89 identified a novel function for the group I PAKs in cell-cell fusion.

90 a potent small molecule inhibitor of group I PAKs reverses dendritic spine phenotypes in Fmr1 KO mice

91 ategy for achieving selectivity over group I PAKs, and the broad kinome, based on unique flexibility

92 We show that the two Drosophila group I PAKs, DPak3 and DPak1, have partially redundant function

93 The pharmacological inhibitor of group I PAKs, IPA-3 partially reduced (-20%) insulin-stimulated

94 dinone, as a potent inhibitor of the group I PAKs.

95 PAKs are subdivided into two groups: type I PAKs (PAK1, PAK2, and PAK3) and type II PAKs (PAK4, PAK5

96 We have now found that the other type I PAKs (PAK2 and PAK3) also fail to target to cell-cell ju

97 Examples are a recently discovered group II PAK (PAK4, -5, -6) selective inhibitor series based on a

98 ubstrate region, indicating a common type II PAK autoregulatory mechanism.

99 e provide a unique understanding for type II PAK regulation.

100 el details that govern regulation of type II PAK signaling.

101 t past the methionine gatekeeper of group II PAKs approached by these type I 1/2 binders were found t

102 Type II PAKs (PAK4, -5, and -6) are recruited to cell-cell bound

103 pe I PAKs (PAK1, PAK2, and PAK3) and type II PAKs (PAK4, PAK5, and PAK6).

104 -guided approach, we discovered that type II PAKs are regulated by an N-terminal autoinhibitory pseud

105 Dysfunction in PAK leads to cofilin activation, drebrin displacement fr

106 The majority of kidney-recipients in PAK group were transplanted at outside institutions and

107 orly conserved, largely disordered region in PAK regulation and raises the possibility that variable

108 counting for the derepression of the T3SS in PAK and the dominant negative effect when it is introduc

109 Inhibiting PKA restored flow-induced PAK and NF-kappaB activation in cells on basement membra

110 ded or inflamed vessels support flow-induced PAK and NF-kappaB activation.

111 sement membrane proteins limit shear-induced PAK activation and inflammation through a protein kinase

112 Inhibiting PAK prevented the enhancement of inflammatory gene expre

113 other factors a long K to PAK time interval; PAK could be a comparable option to SPK for patients wit

114 ancreas-kidney (SPK), pancreas after kidney (PAK) and pancreas transplant alone (PTA).

115 failure subsequent to pancreas after kidney (PAK) are multifactorial; therefore, we examined these fa

116 t outcomes to primary pancreas after kidney (PAK) transplantation.

117 plantation alone, and pancreas after kidney (PAK) transplantations were performed in 42, 67, and 107

118 reas kidney [SPK], 17 pancreas after kidney [PAK]) with a follow-up of a minimum of 12 months were pe

119 , and 47 pancreas transplanted after kidney [PAK]), performed at the University Hospital Innsbruck.

120 Our results demonstrate that Kif3a-PAK signaling coordinates planar polarization of the hai

121 p21-activated kinase (PAK) 2, a member of the PAK family of serine/threonine p

122 ignificant increase in p21-activated kinase (PAK) activity compared with CCS.

123 by activation of Rac1, p21-activated kinase (PAK) and AKT/protein kinase B (AKT) signaling.

124 the phosphorylation of p21-activated kinase (PAK) and extracellular signal-regulated kinase 1/2 (ERK1

125 suppress flow-induced p21 activated kinase (PAK) and nuclear factor (NF)-kappaB activation.

126 s for the RAC effector p21-activated kinase (PAK) are in late-stage clinical development and might im

127 Defects in p21-activated kinase (PAK) are suspected to play a role in cognitive symptoms

128 ted phosphorylation of p21-activated kinase (PAK) as well as its substrates LIM domain kinase and cof

129 The p21-activated kinase (PAK) family of serine/threonine protein kinases plays im

130 as phosphorylation of p21-activated kinase (PAK) in cultured cortical neurons.

131 hly selective group II p21-activated kinase (PAK) inhibitor with a novel binding mode, compound 17.

132 The group I p21-activated kinase (PAK) isoforms PAK1 and PAK2 are activated in response to

133 Signaling through p21-activated kinase (PAK) mediates several of the deleterious effects of shea

134 the activity of P21 (RAC1)-activated kinase (PAK) of group 1.

135 kinase (PI3K)/Akt, and p21-activated kinase (PAK) pathways.

136 roteins, also known as P21-activated kinase (PAK), and the mechanosensitive factor, Yes-associated pr

137 ed Cdc42 kinase (ACK), p21-activated kinase (PAK), and Wiskott-Aldrich syndrome protein (WASP).

138 its downstream target, p21-activated kinase (PAK), are regulators of insulin-stimulated glucose uptak

139 t downstream of Cdc42, p21-activated kinase (PAK), but not Par6 or WASP, may be involved in regulatin

140 phosphorylation by the p21-activated kinase (PAK), Cla4.

141 CK8, through CDC42 and p21-activated kinase (PAK), is unavailable to coordinate cytoskeletal structur

142 t scaffolding protein, p21-activated kinase (PAK), translocates to the membrane after stimulation wit

143 Rac1 and its effector p-21 activated kinase (PAK), two enzymes critically involved in actin managemen

144 nd downstream effector p21-activated kinase (PAK), we further examined Shank3 regulation of NMDARs wh

145 on with LPA as well as p21-activated kinase (PAK)-mediated lamellipodia and filopodia formation follo

146 cytoskeleton dynamics: p21-activated kinase (PAK).

147 ended on the status of p21-activated kinase (PAK).

148 id suppression of Rac1/p21-activated kinase (PAK)/protein kinase C-RAF (C-RAF)/ protein kinase MEK (M

149 ic genetic ablation of p21-activated kinase (PAK)2, but not whole-body PAK1 knockout, impairs glucose

150 Rho-kinase (ROCK) and p21-activated kinase (PAK): ROCK inhibits ULF transport, while PAK stimulates

151 hosphorylated form of p21-associated kinase (PAK), which directly inhibits MLCK.

152 p21-activated kinases (PAK) are a family of serine/threonine kinases downstream

153 The P21-activated kinases (PAK) are emerging antitumor therapeutic targets.

154 cortical activity of p21-activated kinases (PAK), which in turn controls basal body positioning in h

155 -activated serine/threonine protein kinases (PAK)-LIM domain-containing serine/threonine protein kina

156 d activity of Rac and p21-activated kinases (PAKs) and deregulation of cytoskeletal organization.

157 The p21-activated kinases (PAKs) are a family of six serine/threonine kinases that

158 The p21-activated kinases (PAKs) are immediate downstream effectors of the Rac/Cdc4

159 The type II p21-activated kinases (PAKs) are key effectors of RHO-family GTPases involved i

160 p21-activated kinases (PAKs) are serine/threonine kinase effectors of the small

161 p21-activated kinases (PAKs) are serine/threonine protein kinases that serve as

162 tor (ARF) GTPases and p21-activated kinases (PAKs) as its relevant host substrates.

163 p21-activated kinases (PAKs) become activated in cells with acquired drug resis

164 The p21-activated kinases (PAKs) play essential roles in diverse cellular processes

165 Last, p21-activated kinases (PAKs) were downregulated in SAP102 KD neurons.

166 f novel inhibitors to p21-activated kinases (PAKs), major targets of Rac1, on synaptic deterioration

167 tly reported that the p21-activated kinases (PAKs), which are activated by GTP-bound Ras-related C3 b

168 effectors, including p21-activated kinases (PAKs).

169 We substituted the major PAK sites, Ser-672 and Ser-702, with either alanine or a

170 es a potent, orally available small-molecule PAK inhibitor with significant promise for the treatment

171 docking sites for FAK-Src and GIT1/2-PIX-NCK-PAK complex), LD5, and all four carboxyl-terminal LIM do

172 -AD mice were crossed with dominant-negative PAK mice.

173 in 3 (30%) SPK recipients and in 15 (82%) of PAK recipients as early as 14 days posttransplant.

174 Combined absence of PAK-1 and SPC-1 induced complete axis retraction, owing

175 pathology and that therapeutic activation of PAK may exert symptomatic benefits on high brain functio

176 vasion foci, and SopE-mediated activation of PAK recruited MYO6 to actin-rich membranes.

177 n studies showed constitutive association of PAK and Akt, suggesting a possible role of PAK in Akt tr

178 eased our understanding about the biology of PAK family members.

179 In addition, the clearance of PAK (a wild-type P. aeruginosa strain) by primary AMs wa

180 re responsible for the biological effects of PAK family of kinases in cancer cells.

181 In this work, we explore the effects of PAK inhibition on RAC1(P29S) signaling in zebrafish embr

182 The efficacy of PAK inhibitors may have implications in drug discovery f

183 iting apoptosis reduced the cellular exit of PAK.

184 expression and pharmacological inhibition of PAK both disrupt activity-dependent phosphorylation of S

185 eased in edematous tissue, and inhibition of PAK in edematous intestine improved intestinal motility.

186 helial cells via PKA-dependent inhibition of PAK.

187 lopment that can be blocked by inhibitors of PAK or MEK.

188 we have summarized the complex regulation of PAK and its downstream diverse myriads of effectors, whi

189 To determine the role of PAK in AD, we first quantified PAK by immunoblotting in

190 f PAK and Akt, suggesting a possible role of PAK in Akt translocation.

191 chemistry strategies, leading to a series of PAK inhibitors that are orally active in inhibiting tumo

192 ng cofilin, the primary downstream target of PAK and a major actin depolymerizing factor, prevented S

193 of concept for pan-group I, pan-group II, or PAK isoform selective inhibition has yet to be demonstra

194 e infected with P. aeruginosa strain PAO1 or PAK, which expresses ExoS, ExoT, and ExoY, but not ExoU.

195 ned Shank3 regulation of NMDARs when Rac1 or PAK was manipulated.

196 occluded by specific inhibitors for Rac1 or PAK, and was blocked by constitutively active Rac1 or PA

197 was blocked by constitutively active Rac1 or PAK.

198 ange factor beta-PIX/PIX-1 and effector PAK1/PAK-1, and a RhoA-like pathway, involving ROCK/LET-502,

199 nly one compound, an aminopyrazole based pan-PAK inhibitor, entered clinical trials but did not progr

200 din E2-mediated GPCR activation is partially PAK-dependent and likely also involves protein kinase A,

201 r of synapses associated with phosphorylated PAK in adult hippocampal slices from wild-type, but not

202 ght chain, dystrophin, actin polymerization, PAK regulatory genes and oxidative stress response genes

203 e PAK, proteinuria, the occurrence of a post-PAK kidney rejection episode, and interval between kidne

204 In our analysis, post-PAK kidney allograft loss was strongly associated with g

205 galovirus disease, and HbA1C at 6-month post-PAK) and transplant factors (time to PAK, use of inducti

206 pre-PAK and at 3-, 6-, 9-, and 12-month post-PAK, presence of proteinuria, pre- or post-PAK kidney re

207 ould be counseled regarding the risk of post-PAK renal transplant failure.

208 t-PAK, presence of proteinuria, pre- or post-PAK kidney rejection, pancreas rejection, cytomegaloviru

209 s paper, we describe the discovery of potent PAK inhibitors guided by structure-based drug design.

210 r, pre-PAK kidney rejection episode, and pre-PAK proteinuria.

211 ular filtration rate less than 45 mL/min pre-PAK, K to P interval of over 1 year, pre-PAK kidney reje

212 , glomerular filtration rate at 3 months pre-PAK and at 3-, 6-, 9-, and 12-month post-PAK, presence o

213 pre-PAK, K to P interval of over 1 year, pre-PAK kidney rejection episode, and pre-PAK proteinuria.

214 duction in PREX1 binding to PIP3 Like PREX2, PAK-mediated phosphorylation also negatively regulates P

215 Primary PAK transplants (n = 78) were compared to PRT (n=18).

216 iate-term graft survival compared to primary PAK transplantation.

217 e the role of PAK in AD, we first quantified PAK by immunoblotting in homogenates from the parietal n

218 es (LIMK1 and 2) are substrate for Cdc42/Rac-PAK and modulate actin dynamics by phosphorylating cofil

219 can be partially mitigated by increasing Rac-PAK signaling.

220 t evidence that Lis1 regulates localized Rac-PAK signaling in embryonic hair cells, probably through

221 results together indicate that the TRIO-RAC-PAK signaling pathway can be exploited and modulated by

222 on studies revealed that the UNC-73/TRIO-RAC-PAK signaling pathway is activated by ectopic DISC1 in C

223 eir activation by IEM-1460, included the Rac/PAK/LIM-kinase pathway that regulates spine actin dynami

224 Mechanistic studies identified a DBL/RAC1/PAK signaling axis capable of driving resistance to both

225 n and can be accounted for by increased Rac1/PAK- and LIMK-dependent cofilin phosphorylation and acti

226 d the effect of PI3Kdelta inhibition on Rac1/PAK, FAK, and JNK activation.

227 Our studies suggest that Rac1/PAK is key target of PDGF-mediated PI3Kdelta signaling,

228 via CXCR4-dependent stimulation of the Rac1/PAK actin polymerization pathway, leading to increased s

229 from apoptosis by the activation of the Rac1/PAK/AKT signaling cascade in vitro and in vivo.

230 AR hypofunction by interfering with the Rac1/PAK/cofilin/actin signaling, leading to the loss of NMDA

231 0-triggered transient activation of the Rack-PAK-LIMK pathway, and that knockdown of LIMK through siR

232 ocalized and GDP bound and failed to recruit PAK unless mutated to be constitutively active/GAP insen

233 of the prostacyclin analog iloprost reduced PAK activation and inflammatory gene expression at sites

234 ow that these two proteins together regulate PAK-LIMK-Cofilin and cyclin D1/CDK4 pathways.

235 s, synapse formation mediated by EphB/SAP102/PAK signaling in the early postnatal brain may be crucia

236 c oxide production regulates matrix-specific PAK signaling and describe a novel mechanism of nitric o

237 tient/pancreas graft survival rates for SPK, PAK, and PTA were 100%/100%, 100%/100%, and 100%/83%, re

238 patient/graft survival was 100%/100% in SPK, PAK, and PTA.

239 We conclude that pooling the results of SPK, PAK and PTA can produce potentially useful models for re

240 s in the capacity of GIT1-R283W to stimulate PAK phosphorylation in cultured hippocampal neurons.

241 In humans, insulin-stimulated PAK activation was decreased in both acute insulin-resis

242 c1 protein expression and insulin-stimulated PAK(Thr423) phosphorylation were decreased in muscles of

243 e library from the high-T3SS-producer strain PAK was introduced into the low-producer strain PAO1, an

244 anktonic cultures of P. aeruginosa K strain (PAK).

245 such differences in two laboratory strains, PAK and PAO1.

246 Successful PAK offers a survival advantage compared with receiving

247 in kinase (PK)A activation, which suppresses PAK.

248 We conclude that PAK-mediated phosphorylation of PKD1 at Ser(203) trigger

249 Importantly, in vivo data indicated that PAK activity increased in edematous tissue, and inhibiti

250 Kaplan-Meier analysis results showed that PAK after either a living or a deceased donor kidney tra

251 Overall, our data suggest that PAK decrease is a consequence of AD neuropathology and t

252 In addition, the PAK patient developed acute pancreatitis after CAR-T the

253 ll of these associations were ablated by the PAK inhibitor IPA3, suggesting that PAK1 activation lies

254 targeting in lymphoma cells may involve the PAK and Akt signaling pathway, but not the mitogen-activ

255 e 1 (PAK1) and PAK3 belong to group I of the PAK family and control cell movement and division.

256 PAK4 is a member of the PAK family of serine/threonine kinases, which act as eff

257 21-activated kinase (PAK) 2, a member of the PAK family of serine/threonine protein kinases, plays an

258 n protein expression of other members of the PAK family, are present in schizophrenia.

259 nockdown phenotypes, whereas mutation of the PAK phosphorylation site is able to rescue them.

260 These data suggest that suppressing the PAK pathway might be of therapeutic benefit in this type

261 he repression of the T3SS in PAO1, while the PAK genome encodes a defective MexS, accounting for the

262 Mrs6 interacted with the PAK kinase Ste20 and MAPKK Ste7 by two-hybrid analysis.

263 kinase activity and its interaction with the PAK-interacting exchange factor-beta (beta-Pix) are requ

264 udies have established a requirement for the PAKs in the pathogenesis of Neurofibromatosis type 2 (NF

265 These data implicate the PAKs as potential therapeutic targets.

266 at least in part, through inhibition of the PAKs.

267 to negatively regulate signaling through the PAKs and the tumor suppressive functions of Merlin are m

268 that are resistant to the combined therapy, PAKs regulate JNK and beta-catenin phosphorylation and m

269 One of these PAK inhibitors prevented progressive synaptic deteriorat

270 Moreover, this PAK inhibitor--which we call FRAX486--also rescues seizu

271 tonic inhibition of MLCK, presumably through PAK phosphorylation.

272 1 via ROCK, while Rac1 inhibits RhoA through PAK.

273 KA suppressed inflammatory signaling through PAK inhibition.

274 ion entailed among other factors a long K to PAK time interval; PAK could be a comparable option to S

275 bitors of BRAF but are uniquely sensitive to PAK inhibitors.

276 th post-PAK) and transplant factors (time to PAK, use of induction antibody therapy, and combinations

277 Accordingly, we found a decrease of total PAK in the cortex of 12- and 20-month-old 3xTg-AD mice,

278 A loss of total PAK, detected in the cortex of AD patients (-39% versus

279 ival after pancreas after kidney transplant (PAK) has been reported to be inferior to patient surviva

280 ransplant, pancreas after kidney transplant (PAK), and pancreas transplant alone (PTA).

281 hird had a pancreas after kidney transplant (PAK).

282 , and pancreas after kidney transplantation (PAK).

283 K], 5 pancreas after kidney transplantation [PAK], and 6 pancreas transplant alone [PTA]) between Nov

284 Two patients underwent PAK retransplantation diagnosed with acute rejection at

285 xposing cells to four structurally unrelated PAK inhibitors (PF-3758309, FRAX486, FRAX597, and IPA-3)

286 For SPK versus PAK recipients, there was no difference in median of len

287 sored pancreas survival rates for SPK versus PAK were 93% vs. 90%, 90% vs. 90%, and 82% versus 85%, r

288 ctive in translocation (>2 log reduction vs. PAK; P < 0.005).

289 Prominent among these were PAK-interacting exchange factor (known as Pix or RtGEF)

290 on via inhibiting MYPT1 phosphorylation when PAK activity is increased under pathologic conditions.

291 y but not in Rac-induced protrusion, whereas PAK was required for Rac-induced protrusion.

292 gnal, which sets in motion a cascade whereby PAKs phosphorylate and negatively regulate PREX2 to decr

293 To determine whether PAK dysfunction aggravates AD phenotype, 3xTg-AD mice we

294 array, revealed distinct mechanisms by which PAKs mediate resistance to BRAFi and the combined therap

295 se (PAK): ROCK inhibits ULF transport, while PAK stimulates it.

296 tion was determined by pull-down assays with PAK-agarose beads.

297 al was superior in SPK (68.8%) compared with PAK (62.5%) and PTA (16.4%).

298 phorylation of the aspartic acid mutant with PAK resulted in the slow phosphorylation of Thr-627, Ser

299 release, which was dramatically reduced with PAK mutants or in WT PAK-infected primary TLR5(-/-) AMs,

300 amatically reduced with PAK mutants or in WT PAK-infected primary TLR5(-/-) AMs, demonstrating the de